Evidence map›Paper›PMID 38745269›Full record

ArticleMolecular cancer2024

CRISPR-Cas13d screens identify KILR, a breast cancer risk-associated lncRNA that regulates DNA replication and repair.

Lu Wang, Mainá Bitar, Xue Lu, Sebastien Jacquelin, Sneha Nair, Haran Sivakumaran, Kristine M Hillman, Susanne Kaufmann, Rebekah Ziegman, Francesco Casciello and 4 more

Abstract read
In one paragraph

Article in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential.Computational and structural biotechnology journal · 2025
    Review
  12. Review
  13. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lu WangCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Mainá BitarCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Xue LuCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Sebastien JacquelinCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Sneha NairCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Haran SivakumaranCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Kristine M HillmanCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Susanne KaufmannCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Rebekah ZiegmanCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Francesco CascielloCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Harsha GowdaCancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Joseph RosenbluhCancer Research Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.
Stacey L Edwards *Cancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Stacey.Edwards@qimrberghofer.edu.au.
Juliet D French *Cancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Juliet.French@qimrberghofer.edu.au.

Funding

Isabel and Roderic Allpass DonationNational Breast Cancer Foundation of Australia IIRS-23-060National Health and Medical Research Council 1122022National Health and Medical Research Council Senior Research Fellowship 1135932Tour de Cure RSP-225-1819
6 · The paper itself

Abstract

backgroundLong noncoding RNAs (lncRNAs) have surpassed the number of protein-coding genes, yet the majority have no known function. We previously discovered 844 lncRNAs that were genetically linked to breast cancer through genome-wide association studies (GWAS). Here, we show that a subset of these lncRNAs alter breast cancer risk by modulating cell proliferation, and provide evidence that a reduced expression on one lncRNA increases breast cancer risk through aberrant DNA replication and repair.

methodsWe performed pooled CRISPR-Cas13d-based knockdown screens in breast cells to identify which of the 844 breast cancer-associated lncRNAs alter cell proliferation. We selected one of the lncRNAs that increased cell proliferation, KILR, for follow-up functional studies. KILR pull-down followed by mass spectrometry was used to identify binding proteins. Knockdown and overexpression studies were performed to assess the mechanism by which KILR regulates proliferation.

resultsWe show that KILR functions as a tumor suppressor, safeguarding breast cells against uncontrolled proliferation. The half-life of KILR is significantly reduced by the risk haplotype, revealing an alternative mechanism by which variants alter cancer risk. Mechanistically, KILR sequesters RPA1, a subunit of the RPA complex required for DNA replication and repair. Reduced KILR expression promotes breast cancer cell proliferation by increasing the available pool of RPA1 and speed of DNA replication. Conversely, KILR overexpression promotes apoptosis in breast cancer cells, but not normal breast cells.

conclusionsOur results confirm lncRNAs as mediators of breast cancer risk, emphasize the need to annotate noncoding transcripts in relevant cell types when investigating GWAS variants and provide a scalable platform for mapping phenotypes associated with lncRNAs.

Indexed as

Breast NeoplasmsCell ProliferationCRISPR-Cas SystemsDNA RepairDNA ReplicationRNA, Long NoncodingCell Line, TumorFemaleGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansRNA, Long NoncodingBreast cancerCas13 screenCell proliferationCRISPRDNA replicationGenetic variantsGWASlncRNALong noncoding RNA

Identifiers

PMID38745269
PMCPMC11094906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.